RxDoctor Payments Data

Mark Zielinski, MD

Psychiatry · Baton Rouge, LANPI 1194875625

Payments from drug & device makers

$358in general payments, 2019–2025

Across 25 payments — averaging $14.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$76
  • Takeda Pharmaceuticals U.S.A., Inc.$60
  • Shire North American Group Inc$58
  • Tris Pharma Inc$39
  • Orexo US, Inc.$20
  • Ironshore Pharmaceuticals Inc.$19
  • plus $86 from 6 others

What the payments were for

  • Food & beverage$32390%
  • Education$3610%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$358 in reported general payments places this provider in the 40th percentile of 474 psychiatry providers in Louisiana.

See all psychiatry providers in Louisiana

Medicare billing

Part B allowed, 2024
$18,389
Medicare patients
64
Services billed
154

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl17$38,950
RexultiBrexpiprazole11$15,333
Lisdexamfetamine Dimesylate46$9,690
Methylphenidate ErMethylphenidate Hcl41$6,438
Aripiprazole73$3,739
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine126$3,491
Duloxetine Hcl180$3,174
Lamotrigine164$3,146
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine46$3,024
Bupropion XlBupropion Hcl111$2,793
Dextroamphetamine Sulfate21$2,374
Quetiapine Fumarate135$2,354
Divalproex Sodium ErDivalproex Sodium33$2,167
Quetiapine Fumarate ErQuetiapine Fumarate12$1,951
Dexmethylphenidate Hcl ErDexmethylphenidate Hcl18$1,541

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$12$38,95017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 474 psychiatry providers in Louisiana.

Other psychiatry in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →